Open clinical trials · post-viral overlap

Recruiting post-viral overlap clinical trials

Updated October 2026 · 56 trials open to enrolment on ClinicalTrials.gov

Last updated 07 October 2026 from ClinicalTrials.gov. Trial statuses are refreshed automatically; check the registry record for the latest status and contact details.

56 open trials35 recruiting16 not yet recruiting5 enrolling by invitation155 total post-viral overlap trials tracked

This page lists every interventional study for overlapping or unspecified post-viral conditions (post-COVID fatigue, dysautonomia, POTS, post-viral syndromes not labelled as Long COVID or ME/CFS) that ClinicalTrials.gov currently shows as recruiting, not yet recruiting or enrolling by invitation. It is rebuilt automatically from the registry so it stays current without manual curation.

Of 56 open trials, 35 are actively recruiting, 16 are registered but not yet open, and 5 enrol by invitation only. 21 are phased drug or biologic studies; the rest are behavioural, rehabilitation, device or other non-drug interventions, which the registry labels "phase not applicable". Frequently tested interventions right now include Cromolyn Sodium, Counterpressure Maneuvers, Droxidopa Oral Product, Delivery Of A Long-Term Holter 21 Days Or Placement Of An Implantable Holter From The Outset So Syncope, 5 Ml Of 0.25% Bupivacaine With Epinephrine, Tms, Tdcs, Bilateral Sequential Stellate Ganglion Block.

Looking for trials that have finished? See the complete post-viral overlap trial list (155 trials including completed and terminated studies), or use the interactive trial finder to filter by agent, phase, sponsor and status.

How to read this list. Trials are grouped first by recruitment status, then by phase (later phases first). Each card shows the registry ID, sponsor, intervention(s) tested, planned start and primary-completion dates and target enrollment, plus a short summary trimmed from the registry description. Our extract does not include site locations or eligibility criteria, so open the record to see where a study enrols, who qualifies and whom to contact.
⚠️
Not medical advice. This page is an automatically compiled index of entries on ClinicalTrials.gov. Listing here is not an endorsement of any trial, sponsor or treatment, and trial status can change between our refreshes. Always confirm details on ClinicalTrials.gov and discuss participation with your own clinician.

Recruiting (35)

Actively enrolling. Contact details and sites are on the ClinicalTrials.gov record.

Phase 4 (4)

RecruitingPhase 4 NCT07468604
Sponsor: University Health Network, Toronto (Academic / non-profit / other)
Intervention(s): 5 Ml Of 0.25% Bupivacaine With Epinephrine
Start: May 2026  |  Primary completion: May 2027  |  Enrollment: 78 (estimated)
Record last updated: Sep 2026

Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations, and orthostatic intolerance, at an annual cost of CAD $1,675-$7,340 per case.

View on ClinicalTrials.gov ↗
RecruitingPhase 4 NCT04308278
Sponsor: Labo'Life (Industry)
Intervention(s): 2Lebv® / 2Lxfs®
Start: Jan 2021  |  Primary completion: Aug 2028  |  Enrollment: 88 (estimated)
Record last updated: Aug 2026

Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may cause different diseases. In most cases, EBV infection is asymptomatic because of a highly effective host immune response.

View on ClinicalTrials.gov ↗
RecruitingPhase 4 NCT06695910
Sponsor: Samuel Fortin (Industry)
Intervention(s): Monoglyceride Eicosapentaenoic Acid, Sunflower Oil
Start: Nov 2024  |  Primary completion: May 2027  |  Enrollment: 48 (estimated)
Record last updated: Dec 2025

A growing body of studies shows that omega-3s act directly in molecular signaling pathways that reduce inflammation and are thought to have a positive effect on cognitive health. Brain fog is a term that has been popularized in the medical world in the wake of the COVID-19 pandemic. A significant proportion of patients with long COVID reported having cognitive sequelae that were like fogginess.

View on ClinicalTrials.gov ↗
RecruitingPhase 4 NCT06792214
Sponsor: Mount Sinai Hospital, Canada (Academic / non-profit / other)
Start: Jan 2025  |  Primary completion: Jan 2026  |  Enrollment: 118 (estimated)
Record last updated: Jan 2025

The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.

View on ClinicalTrials.gov ↗

Phase 2 (6)

RecruitingPhase 2 NCT00409435
Sponsor: Mayo Clinic (Academic / non-profit / other)
Intervention(s): Pyridostigmine
Start: Oct 2006  |  Primary completion: Feb 2027  |  Enrollment: 50 (estimated)
Record last updated: Mar 2026

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT06073886
Sponsor: University of California, Los Angeles (Academic / non-profit / other)
Intervention(s): Active Ctbs, Imaginal Exposure
Start: Mar 2024  |  Primary completion: Jul 2026  |  Enrollment: 75 (estimated)
Record last updated: Feb 2026

The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT07197905
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Intravenous Iron
Start: Nov 2025  |  Primary completion: Oct 2026  |  Enrollment: 12 (estimated)
Record last updated: Dec 2025

People with postural orthostatic tachycardia syndrome (POTS) often have low red blood cell volumes and low ferritin in their blood (a marker of iron storage in the body). The purpose of this pilot study is to investigate whether giving iron to people with POTS who have low ferritin levels will increase the red blood cell volume and improve POTS symptoms.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT05375968
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Compare Change Is Svc And Sma Flow Due To Gip Antagonist Gip(3-30)Nh2, Compare Change Is Svc And Sma Flow Due To Saline
Start: Feb 2023  |  Primary completion: May 2027  |  Enrollment: 50 (estimated)
Record last updated: Dec 2025

Postural tachycardia syndrome (POTS) affects ≈3 million young people, characterized by chronic presyncopal symptoms characterized by dizziness, lightheadedness, and orthostatic tachycardia that occur while standing.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT04186286
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Ivabradine 4-Week Course, Propranolol 4-Week Course
Start: Feb 2021  |  Primary completion: Dec 2025  |  Enrollment: 20 (estimated)
Record last updated: May 2024

1.0 BACKGROUND Postural tachycardia syndrome (POTS) is a disorder of chronic orthostatic intolerance characterized by symptoms of palpitations, lightheadedness, chest discomfort, shortness of breath, blurred vision, and mental clouding. These symptoms occur during standing and are associated with a marked increase in heart rate (HR) in the absence of hypotension, which typically resolve when sitting or lying down.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT06012552
Sponsor: Military Institute od Medicine National Research Institute (Academic / non-profit / other)
Intervention(s): Tianeptine
Start: Feb 2023  |  Primary completion: Apr 2027  |  Enrollment: 140 (estimated)
Record last updated: Aug 2023

COVID-19 is associated with a high risk of complications from the central nervous system. Syndrome of cognitive disorders- in terms of memory, attention or executive functions among COVID-19 convalescents is often called brain fog (covid fog - CF). CF leads to psychomotor retardation and chronic fatigue syndrome, resulting in poor functioning and low quality of life.

View on ClinicalTrials.gov ↗

Phase 1 (1)

RecruitingPhase 1 NCT07398508
Sponsor: Stephen G. Kaler (Academic / non-profit / other)
Intervention(s): Droxidopa Oral Product
Start: Aug 2026  |  Primary completion: Jun 2030  |  Enrollment: 6 (estimated)
Record last updated: Oct 2026

This clinical trial will evaluate the safety, tolerability, dosing, and efficacy of Northera (Droxidopa) in children with Menkes disease aged 7 to 17 years who survived the major neurodegenerative and neurocognitive effects of Menkes disease through early Copper Histidinate treatment.

View on ClinicalTrials.gov ↗

Phase not applicable (24)

RecruitingPhase not applicable NCT05493605
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild (Research network)
Intervention(s): Delivery Of A Long-Term Holter 21 Days Or Placement Of An Implantable Holter From The Outset So Syncope
Start: Mar 2023  |  Primary completion: Mar 2029  |  Enrollment: 150 (estimated)
Record last updated: Oct 2026

Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07655375
Sponsor: Guy Boeckxstaens (Academic / non-profit / other)
Intervention(s): Sample Collection
Start: Aug 2026  |  Primary completion: Oct 2027  |  Enrollment: 60 (estimated)
Record last updated: Sep 2026

Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success. Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05554107
Sponsor: Lund University (Academic / non-profit / other)
Intervention(s): Training Program
Start: Nov 2022  |  Primary completion: Mar 2028  |  Enrollment: 200 (estimated)
Record last updated: Sep 2026

Postural orthostatic tachycardia syndrome (POTS) is a disorder of unknown origin characterized by orthostatic intolerance and increased heart rate (HR) of ≥ 30 beats/minute during orthostasis in the absence of orthostatic hypotension.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05400174
Sponsor: University of California, San Diego (Academic / non-profit / other)
Intervention(s): Tilt Table
Start: Dec 2021  |  Primary completion: Dec 2026  |  Enrollment: 60 (estimated)
Record last updated: Aug 2026

Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Besides causing symptoms that impair movement, PD also causes non-motor symptoms, such as problems thinking and orthostatic hypotension (OH), i.e., low blood pressure (BP) when standing.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05947136
Sponsor: Centre Leon Berard (Academic / non-profit / other)
Intervention(s): Interpretation Of The Results From The Detection Visit, Explaining Detection Results And Referrals To The Patient, Early Medical Care Through The Network
Start: Jan 2024  |  Primary completion: Jun 2028  |  Enrollment: 204 (estimated)
Record last updated: Jun 2026

This is a prospective, multicentre, phase III, randomised, controlled intervention study. Two groups of patients with equal numbers will be studied and each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1).

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07579026
Sponsor: Riphah International University (Academic / non-profit / other)
Start: Aug 2025  |  Primary completion: Sep 2026  |  Enrollment: 44 (estimated)
Record last updated: May 2026

Postural orthostatic tachycardia POTS is characterized by excessive increase in heart rate when moving from lying to standing position, often accompanied by symptoms such as dizziness, fatigue, brain fog, lightheadedness, rapid heartbeat and palpitation.it most commonly effects the females of reproductive age and can be triggered by events like viral infections, trauma and hormonal changes.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05924646
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Microcystalline Cellulose Capsules
Start: May 2024  |  Primary completion: Jun 2028  |  Enrollment: 50 (estimated)
Record last updated: May 2026

Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05914649
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Iv Normal Saline
Start: Sep 2024  |  Primary completion: Dec 2030  |  Enrollment: 100 (estimated)
Record last updated: May 2026

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT04881318
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Waist-High Compression Tights, Abdominal Compression Garments, Medications That Modulate Heart Rate And Blood Pressure
Start: May 2021  |  Primary completion: Dec 2026  |  Enrollment: 30 (estimated)
Record last updated: May 2026

Compression Garments are a commonly prescribed treatment in Postural Orthostatic Tachycardia Syndrome (POTS). The effectiveness of a proof-of-concept compression garment has been demonstrated in an acute laboratory setting. It is not known if commercially available compression garments that participants wear in their every day lives are effective at improving heart rate and reducing symptoms in POTS.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT04271878
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Respiract™ System
Start: Feb 2022  |  Primary completion: Dec 2029  |  Enrollment: 26 (estimated)
Record last updated: May 2026

The mechanism behind postural orthostatic tachycardia syndrome (POTS) involves many causes including a sympathetic nervous system problem. Blood gases, like carbon dioxide (CO2), have an important effect on sympathetic activation. The purpose of this research study is to determine if higher CO2 levels have any effect in lowering heart rate and reducing POTS symptoms when upright/standing.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05633693
Sponsor: Simon Fraser University (Academic / non-profit / other)
Intervention(s): Counterpressure Maneuvers, Baseline Stand
Start: Apr 2023  |  Primary completion: May 2027  |  Enrollment: 30 (estimated)
Record last updated: Apr 2026

The investigators are interested in whether discrete counterpressure maneuvers, or muscle movements in the lower body, will boost blood pressure and cardiovascular control in children who faint.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05555771
Sponsor: Dr. Victoria Claydon (Academic / non-profit / other)
Intervention(s): Counterpressure Maneuvers
Start: Sep 2022  |  Primary completion: Sep 2027  |  Enrollment: 300 (estimated)
Record last updated: Apr 2026

The investigators will assess the efficacy of clinically recommended counterpressure maneuvers (CPM) in preventing syncope for paediatric patients. Participants presenting to the emergency department (ED) will first provide written informed consent. In stage I, they will be asked to complete a brief survey documenting the presentation of their syncopal episode, and any prodromal symptoms they experienced.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05618054
Sponsor: Virginia Commonwealth University (Academic / non-profit / other)
Intervention(s): Looming Task
Start: Mar 2023  |  Primary completion: Dec 2026  |  Enrollment: 36 (estimated)
Record last updated: Apr 2026

This study is being conducted to see how people with Postural tachycardia syndrome (POTS) make sense of the things they see. The information may help doctors to learn more about how the different parts of people's brains communicate.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05748015
Sponsor: Istituti Clinici Scientifici Maugeri SpA (Academic / non-profit / other)
Intervention(s): Quantification Of Sensory And Autonomic Small Nerve Fibers By Punch Skin Biopsy, Cardiovascular Reflexes Testing, Administration Of Clinical Scales Evaluating Autonomic Symptoms, Pain Small Fiber Neuropathy Symptoms
Start: Mar 2021  |  Primary completion: Nov 2026  |  Enrollment: 60 (estimated)
Record last updated: Apr 2026

The goal of this interventional non-pharmacological study is to evaluate the involvement of the autonomic nervous system in patients with relapsing-remitting and primary progressive multiple sclerosis.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06292377
Sponsor: Brugmann University Hospital (Academic / non-profit / other)
Intervention(s): Ecg, Transthoracic Echography, Blood Sampling
Start: Jun 2024  |  Primary completion: Dec 2027  |  Enrollment: 250 (estimated)
Record last updated: Mar 2026

Stroke is worldwide the second most common cause of death following heart attack and the leading cause of disability. Post-stroke fatigue (PSF) is a common complication after stroke and can be defined as 'an overwhelming exhaustion or tiredness, not related to exertion, which does not typically improve with rest'. Fatigue following stroke can be divided into early (\< 3 months) and late (\> 3 months) fatigue.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT01912313
Sponsor: KU Leuven (Academic / non-profit / other)
Intervention(s): Rectal Biopsies From Ibs Patients Or Healthy Subjects Will Be Taken During Proctoscopy
Start: Aug 2013  |  Primary completion: Dec 2026  |  Enrollment: 99999999 (estimated)
Record last updated: Mar 2026

Rectal biopsies from IBS patients or healthy subjects will be taken.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07478172
Sponsor: University of Missouri-Columbia (Academic / non-profit / other)
Intervention(s): Whole-Body Electrical Muscle Stimulation Exercise
Start: Mar 2026  |  Primary completion: Dec 2030  |  Enrollment: 50 (estimated)
Record last updated: Mar 2026

This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07455994
Sponsor: Centre Hospitalier Universitaire de Saint Etienne (Academic / non-profit / other)
Intervention(s): Neurocoach® And Sudoscan®
Start: Dec 2025  |  Primary completion: Dec 2026  |  Enrollment: 100 (estimated)
Record last updated: Mar 2026

Some physiological factors, such as physical activity, or pathological factors, such as sepsis or diabetes, are known to modulate the overall autonomic activity and the individual's intrinsic capacity to regulate their sympathetic and parasympathetic balance.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06863207
Sponsor: Medical College of Wisconsin (Academic / non-profit / other)
Intervention(s): Percutaneous Electrical Nerve Field Stimulation, Hypnotherapy
Start: Jan 2025  |  Primary completion: Dec 2028  |  Enrollment: 120 (estimated)
Record last updated: Feb 2026

Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsia, irritable bowel) rather than underlying pathophysiology.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05212129
Sponsor: Medical College of Wisconsin (Academic / non-profit / other)
Intervention(s): Percutaneous Vagal Nerve Stimulation (Pvns) Device, Acoustic Vagal Nerve Stimulation (Avns) Treatment
Start: Apr 2021  |  Primary completion: Dec 2026  |  Enrollment: 90 (estimated)
Record last updated: Feb 2026

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS).

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07019519
Sponsor: University of Copenhagen (Academic / non-profit / other)
Intervention(s): Gipr Antagonist, Glp-1R Antagonist, Cck Agonist
Start: Mar 2025  |  Primary completion: Jun 2026  |  Enrollment: 30 (estimated)
Record last updated: Jun 2025

This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in healthy. This is addressed by hormone infusions during MR-scans of the abdomen and intake of oral glucose.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06936319
Sponsor: Medical University Innsbruck (Academic / non-profit / other)
Intervention(s): Best Clinical Practice Plus Cpm-Biofeedback Training, Best Clinical Practice
Start: Jan 2025  |  Primary completion: Dec 2025  |  Enrollment: 40 (estimated)
Record last updated: May 2025

The present study evaluates whether performing a 14-days counter pressure maneuvers (CPM)-biofeedback training improves the symptomatic burden (primary objective) and secondarily the interference of POTS symptoms with daily activities, fatigue, and health-related quality of life of individuals with POTS compared to best clinical practice non-pharmacological measures.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06817707
Sponsor: Centre Hospitalier Universitaire de Nice (Academic / non-profit / other)
Intervention(s): Evaluation Of Urinary Dysfunction In Patients With Canvas
Start: Mar 2025  |  Primary completion: Mar 2027  |  Enrollment: 40 (estimated)
Record last updated: Mar 2025

The investigator wishes to evaluate the prevalence of urinary symptoms in patients diagnosed with Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS). As much as one third of patients living with CANVAS experience symptoms of urinary system dysfunction.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT04151693
Sponsor: Joint Authority for Päijät-Häme Social and Health Care (Academic / non-profit / other)
Intervention(s): Health Psychological Group Rehabilitation For Patients With Chronic Fatigue Syndrome
Start: Nov 2019  |  Primary completion: May 2028  |  Enrollment: 80 (estimated)
Record last updated: Apr 2024

Chronic fatigue syndrome (ME/CFS) is a severe medical condition. It is characterized by long term fatique and other persisted symptoms, such as a cognitive disabilities and orthostatic intolerance. Symptoms limit a persons ability to carry out ordinary daily activities.

View on ClinicalTrials.gov ↗

Not yet recruiting (16)

Registered but not yet open. The planned start date is an estimate; some sponsors accept expressions of interest early.

Phase 4 (2)

Not yet recruitingPhase 4 NCT05363514
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Low Dose Naltrexone, Microcrystalline Cellulose
Start: Jul 2026  |  Primary completion: Jun 2029  |  Enrollment: 80 (estimated)
Record last updated: May 2026

Many patients with Postural Orthostatic Tachycardia Syndrome (POTS) experience debilitating fatigue and this significantly impacts their daily lives. Unfortunately, there are no treatments to help POTS patients with their fatigue. One medication, called low dose naltrexone (LDN), has been tested as a treatment for fatigue in other medical conditions.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 4 NCT07077278
Sponsor: Stanford University (Academic / non-profit / other)
Intervention(s): Low Sodium Oxybate
Start: Oct 2025  |  Primary completion: Sep 2027  |  Enrollment: 25 (estimated)
Record last updated: Jul 2025

The investigators hope to learn if low sodium oxybate (LXB) is an effective treatment for symptoms of idiopathic hypersomnia (IH) and postural tachycardia syndrome (POTS). Previous research has shown that patients with IH also report having symptoms associated with POTS. The researchers have observed that in patients with both IH and POTS, when patients' sleep quality improves, so do their POTS symptoms.

View on ClinicalTrials.gov ↗

Phase 2 (3)

Not yet recruitingPhase 2 NCT07585513
Sponsor: Cedars-Sinai Medical Center (Academic / non-profit / other)
Intervention(s): Mirabegron
Start: May 2026  |  Primary completion: May 2028  |  Enrollment: 36 (estimated)
Record last updated: May 2026

The study will test the hypothesis that mirabegron is more effective than a placebo in alleviating postural orthostatic tachycardia (POTS) symptoms.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT07526558
Sponsor: University of North Carolina, Chapel Hill (Academic / non-profit / other)
Intervention(s): Ketotifen, Fexofenadine, Cromolyn Sodium
Start: Apr 2026  |  Primary completion: Jan 2027  |  Enrollment: 50 (estimated)
Record last updated: Apr 2026

This is a Phase II double-blinded study to assess the safety, tolerability, and feasibility of the mast cell stabilizing medications ketotifen and cromolyn compared to participants receiving standard of care treatment with fexofenadine alone in participants who have persistent symptoms of mast cell activation following a documented tick-borne illness (Ehrlichiosis, Rocky Mountain Spotted Fever, Alpha-gal Syndrome).

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT07089719
Sponsor: Assistance Publique - Hôpitaux de Paris (Academic / non-profit / other)
Intervention(s): Bevacizumab Injection
Start: Oct 2025  |  Primary completion: Jan 2028  |  Enrollment: 21 (estimated)
Record last updated: Jul 2025

The aim of this research is to evaluate an innovative treatment, Bevacizumab, in patients suffering from respiratory complications related to COVID-19. These complications, particularly difficulty breathing (dyspnea) and impaired lung function, are common in some individuals after infection.

View on ClinicalTrials.gov ↗

Phase 1 (1)

Not yet recruitingPhase 1 NCT07675876
Sponsor: Carcinex Inc (Industry)
Intervention(s): Cromolyn Sodium
Start: Aug 2026  |  Primary completion: Jun 2027  |  Enrollment: 10 (estimated)
Record last updated: Jul 2026

This prospective, open-label pilot study is designed to evaluate the safety, tolerability, feasibility, and preliminary clinical activity of inhaled cromolyn sodium administered by dry powder inhalation in participants with locally advanced lung cancer. Cromolyn sodium is an FDA-approved mast cell stabilizer with an established safety profile in respiratory disease.

View on ClinicalTrials.gov ↗

Early Phase 1 (1)

Not yet recruitingEarly Phase 1 NCT07757555
Sponsor: Johns Hopkins University (Academic / non-profit / other)
Intervention(s): Guanfacine, Cromolyn Sodium
Start: Aug 2026  |  Primary completion: Dec 2027  |  Enrollment: 25 (estimated)
Record last updated: Aug 2026

The goal of this clinical trial is to learn whether guanfacine or cromolyn sodium can improve symptoms and physical functioning in adults with Postural Orthostatic Tachycardia Syndrome (POTS). Both medications are FDA-approved for other conditions but are investigational for the treatment of POTS.

View on ClinicalTrials.gov ↗

Phase not applicable (9)

Not yet recruitingPhase not applicable NCT07842302
Sponsor: Universitat Oberta de Catalunya (Academic / non-profit / other)
Intervention(s): Tms, Tdcs
Start: Sep 2026  |  Primary completion: May 2029  |  Enrollment: 80 (estimated)
Record last updated: Sep 2026

Multiple Sclerosis (MS) is a chronic neurological disease impacting 2.8 million individuals globally, with fatigue being its most debilitating symptom, reported by 75% of patients. Despite its prevalence, the pathophysiology of MS-related fatigue remains poorly understood, and current pharmacological treatments have limited effectiveness.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07837804
Sponsor: University Medical Centre Ljubljana (Academic / non-profit / other)
Intervention(s): Bilateral Sequential Stellate Ganglion Block
Start: Oct 2026  |  Primary completion: Oct 2027  |  Enrollment: 30 (estimated)
Record last updated: Sep 2026

RESET-POTS is a pilot study for adults with postural orthostatic tachycardia syndrome (POTS), a condition that can cause a rapid increase in heart rate, dizziness, weakness, fatigue and other symptoms when standing. The study has two parts.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT05618067
Sponsor: Virginia Commonwealth University (Academic / non-profit / other)
Intervention(s): Breathing Exercise Training
Start: Jan 2028  |  Primary completion: Dec 2028  |  Enrollment: 12 (estimated)
Record last updated: Sep 2026

This study is being to see if participating in breathing exercise training and practicing this training will help with Postural tachycardia syndrome (POTS). The information may help doctors to learn more about how the different parts of people's brains communicate.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07600320
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Fareon Device
Start: May 2026  |  Primary completion: Apr 2027  |  Enrollment: 30 (estimated)
Record last updated: May 2026

The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME/CFS), and other neurodegenerative diagnoses including but not limited to Alzheimer's disease and to collect data on safety and efficacy to inform the design of larger clinical studies.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07409363
Sponsor: University of Leeds (Academic / non-profit / other)
Intervention(s): Active Vagus Nerve Stimulation
Start: May 2026  |  Primary completion: Jul 2026  |  Enrollment: 12 (estimated)
Record last updated: May 2026

Chronic musculoskeletal (MSK) pain affects an estimated 20-33% of the global population and is frequently associated with autonomic nervous system dysfunction, characterised by symptoms such as orthostatic intolerance, palpitations, gastrointestinal dysmotility, and fatigue. Conventional treatments often fail to address this autonomic component, limiting their effectiveness.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07259902
Sponsor: University of Milan (Academic / non-profit / other)
Intervention(s): Fmri
Start: Jan 2026  |  Primary completion: Jan 2030  |  Enrollment: 60 (estimated)
Record last updated: Dec 2025

Temporomandibular disorders (TMD) are among the most common causes of chronic pain worldwide. It is estimated that about 5-12% of the global population is affected, and some conditions, such as arthritis, may be causative factors. Depending on severity, the joints involved can affect multiple functions of the masticatory system, such as the ability to speak, chew, swallow, limit facial expressions, and even breathe.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT06953661
Sponsor: Stanford University (Academic / non-profit / other)
Intervention(s): Stellate Ganglion Block, Ropivacaine, Normal Saline
Start: Oct 2025  |  Primary completion: Nov 2026  |  Enrollment: 20 (estimated)
Record last updated: Oct 2025

This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07163130
Sponsor: Aristotle University Of Thessaloniki (Academic / non-profit / other)
Intervention(s): Transcutaneous Auricular Vagus Nerve Stimulation
Start: Sep 2025  |  Primary completion: Dec 2026  |  Enrollment: 24 (estimated)
Record last updated: Sep 2025

Postural Tachycardia Syndrome (POTS) is a form of dysautonomia characterized by an abnormal cardiovascular response to orthostatic challenges. Individuals afflicted with POTS typically exhibit a heart rate increase of more than 30 beats per minute (bpm) within 10 minutes of assuming an upright posture from a supine or sitting position.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT05796154
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Ear Blood Pressure Monitor
Start: Jun 2025  |  Primary completion: Dec 2025  |  Enrollment: 30 (estimated)
Record last updated: Dec 2024

the investigators propose studies of a tiny, wearable, wireless, beat-to-beat blood pressure monitor that will be both a transformative research platform and an enabler of patient self-care in the diagnosis, investigation, and management of POTS.

View on ClinicalTrials.gov ↗

Enrolling by invitation (5)

Participants are invited from a pre-selected group; the public generally cannot volunteer.

Phase 2 (3)

Enrolling by invitationPhase 2 NCT05350774
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) (NIH)
Intervention(s): Iv Normal Saline, Iv Immunoglobulin
Start: Jul 2023  |  Primary completion: Dec 2026  |  Enrollment: 45 (estimated)
Record last updated: Aug 2026

COVID-19 can cause problems in different parts of the body. For most people, it causes fevers or trouble breathing. Some people might not recover all the way.

View on ClinicalTrials.gov ↗
Enrolling by invitationPhase 2 NCT07567274
Sponsor: Leading Edge Clinic (Academic / non-profit / other)
Intervention(s): Dmso-Based Otic Solution With Betahistine, Dexamethasone, And Lidocaine, N-Acetylcysteine (NAC)
Start: May 2026  |  Primary completion: Jul 2026  |  Enrollment: 20 (estimated)
Record last updated: May 2026

The goal of this clinical trial is to test a compounded dimethyl sulfoxide (DMSO)-based dual-route therapy for adults with refractory subjective tinnitus linked to long-COVID (post-acute sequelae of SARS-CoV-2) or post-COVID-19 vaccine injury. Participants have bothersome tinnitus that has not improved with at least two prior standard treatments.

View on ClinicalTrials.gov ↗
Enrolling by invitationPhase 2 NCT06148311
Sponsor: NYU Langone Health (Academic / non-profit / other)
Intervention(s): Dexmedetomidine
Start: Jul 2024  |  Primary completion: Jan 2027  |  Enrollment: 15 (estimated)
Record last updated: Apr 2026

The purpose of this placebo controlled interventional study is to collect preliminary data on administering dexmedetomidine in patients with Familial Dysautonomia (FD) during a rapid cessation of autonomic crisis. The primary aims are to assess the feasibility and evaluate if measurements of heart rate, blood pressure and oxygen saturation can predict the start of an autonomic crisis. Funding Source- FDA OOPD.

View on ClinicalTrials.gov ↗

Phase not applicable (2)

Enrolling by invitationPhase not applicable NCT07320937
Sponsor: ShuGuang Hospital (Academic / non-profit / other)
Intervention(s): "Yiqi Fuyuan Paste Formula" Test Group
Start: Dec 2025  |  Primary completion: Aug 2026  |  Enrollment: 80 (estimated)
Record last updated: Jan 2026

The goal of this clinical trial is to learn if "Yiqi Fuyuan Paste Formula" (a traditional Chinese medicinal paste made from medicinal and edible Chinese medicines and health food like Ginseng Radix et Rhizoma, Astragali Radix et Rhizoma, Codonopsis Radix, Atractylodis Macrocephalae Rhizoma, Poria Cocos, Coicis Semen, Dioscoreae Rhizoma, Nelumbinis Semen, Angelicae Sinensis Radix, Lycii Fructus, Citri Reticulatae Pericarpium, Juglandis Semen, Longan Arillus, Sesami Nigri Semen, Jujubae Fructus, Glycyrrhizae Radix…

View on ClinicalTrials.gov ↗
Enrolling by invitationPhase not applicable NCT02725060
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Phenylephrine, Isoproterenol, 25 Micro-Ci Of Radiation, 24-Hour Heart Rhythm And Blood Pressure Monitoring, Quantitative Axonal Sudomotor Reflex Testing, Autonomic Function Tests, Rebreathing Test, Assessment Of Splanchnic Capacitance, Microneurography
Start: Feb 2016  |  Primary completion: Oct 2026  |  Enrollment: 58 (estimated)
Record last updated: Nov 2025

The purpose of this study is to see if some people with postural tachycardia syndrome (POTS) have higher levels of immune proteins (autoantibodies) directed against receptors of the autonomic nervous system, and if these autoantibodies make a difference in their POTS symptoms. The investigators also want to see if the levels of these autoantibodies stay the same over time.

View on ClinicalTrials.gov ↗

Frequently asked questions

How do I join a clinical trial?

Open the trial's ClinicalTrials.gov record (the "View on ClinicalTrials.gov" button), read the Eligibility Criteria and Contacts and Locations sections, and contact the study team listed there. Trials only enrol at the sites shown in the record, so check whether a site is near you or whether the study is remote/decentralised. Your own clinician can help you judge whether a trial is a sensible option and may need to provide medical records.

What do the trial phases mean?

Early Phase 1 / Phase 1 studies test safety and dosing in a small group. Phase 2 studies look for a signal of benefit in a larger group and keep checking safety. Phase 3 studies are large confirmatory trials designed to show whether a treatment works well enough for approval. Phase 4 studies follow approved treatments after they reach the market. "Phase not applicable" is used by the registry for behavioural, device, rehabilitation and other non-drug interventions.

What is the difference between recruiting, not yet recruiting and enrolling by invitation?

Recruiting means the study is actively enrolling participants. Not yet recruiting means the study is registered but has not opened enrolment; you can often register interest with the contact listed. Enrolling by invitation means participants are selected from a pre-defined group (for example an existing cohort) and the public generally cannot volunteer.

Does the Open Source Medicine Foundation run these trials?

No. OSMF does not sponsor, run or recruit for any trial on this page. We compile public registry entries from ClinicalTrials.gov so patients and clinicians can find them in one place. For questions about a specific study, contact the sponsor or study team listed on its ClinicalTrials.gov record.

How often is this list updated?

The underlying dataset is rebuilt automatically from the ClinicalTrials.gov API and these pages are regenerated from it. The date at the top of the page is the last successful refresh. Registry entries can lag the real-world status of a study, so a trial shown as recruiting may already be full.

Why is a trial I know about missing?

Our search targets interventional studies whose registered conditions map to Long COVID / PASC, ME/CFS or overlapping post-viral syndromes. Observational studies, trials registered only on non-US registries (EU CTR, ISRCTN, ANZCTR, etc.), and trials whose condition terms did not match our mapping are not included. The full ClinicalTrials.gov search is always more complete than any curated index.

Get new recruiting trials in your inbox.

We summarise newly registered post-viral trials and notable results on the OSMF Substack.

Subscribe on Substack
Cite this page
Open Source Medicine Foundation. Recruiting post-viral overlap clinical trials (updated October 2026). Research Tracker, 07 October 2026. https://research.opensourcemed.info/trials/post-viral-overlap-recruiting.html
Underlying dataset (JSON, CC BY 4.0): https://research.opensourcemed.info/data/clinical_trials/clinical_trials_current.json. Source records: ClinicalTrials.gov.

Related: post-viral overlap research hub · trials by therapeutic agent · all post-viral overlap trials · interactive trial finder.